A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects With Allergic Diseases

NCT05564221 PHASE1 COMPLETED

This study aims to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles following multiple subcutaneous injections of YH35324 in healthy subjects or subjects with allergic diseases, who have atopy.

Details

Lead sponsor	Yuhan Corporation
Phase	PHASE1
Status	COMPLETED
Enrolment	46
Start date	Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Nov 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Atopic Healthy Subjects
• Adult Subjects With Allergic Diseases

Interventions

• YH35324
• Placebo
• Omalizumab

Countries

South Korea